Cargando…

Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study

BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs...

Descripción completa

Detalles Bibliográficos
Autores principales: Hyun, Hakjun, Choi, Min Joo, Heo, Jung Yeon, Seo, Yu Bin, Nham, Eliel, Yoon, Jin Gu, Seong, Hye, Noh, Ji Yun, Cheong, Hee Jin, Kim, Woo Joo, Choi, Ju-Yeon, Lee, Young Jae, Lee, Hye Won, Kim, Sung Soon, Kim, Byoungguk, Song, Joon Young
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Korean Academy of Medical Sciences 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274104/
https://www.ncbi.nlm.nih.gov/pubmed/35818701
http://dx.doi.org/10.3346/jkms.2022.37.e210
_version_ 1784745232519135232
author Hyun, Hakjun
Choi, Min Joo
Heo, Jung Yeon
Seo, Yu Bin
Nham, Eliel
Yoon, Jin Gu
Seong, Hye
Noh, Ji Yun
Cheong, Hee Jin
Kim, Woo Joo
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young
author_facet Hyun, Hakjun
Choi, Min Joo
Heo, Jung Yeon
Seo, Yu Bin
Nham, Eliel
Yoon, Jin Gu
Seong, Hye
Noh, Ji Yun
Cheong, Hee Jin
Kim, Woo Joo
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young
author_sort Hyun, Hakjun
collection PubMed
description BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. METHOD: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-γ enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. RESULTS: Fifty participants aged ≥ 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 ± 3.0 U/mL at 3–4 weeks, 55.7 ± 2.4 U/mL at 5–8 weeks, and 81.3 ± 2.5 U/mL at 10–12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS-CoV-2 were 164.6 ± 4.6 at 3-4 weeks, 313.9 ± 3.6 at 5–8 weeks, and 124.4 ± 2.6 at 10–12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/10(6) peripheral blood mononuclear cell was 25.0 (5.0–29.2) at baseline, 60.0 (23.3–178.3) at 5-8 weeks, and 35.0 (13.3–71.7) at 10–12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1–2, and resolved within two days. CONCLUSION: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5–8 weeks and rather decrease at 10–12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible.
format Online
Article
Text
id pubmed-9274104
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher The Korean Academy of Medical Sciences
record_format MEDLINE/PubMed
spelling pubmed-92741042022-07-21 Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study Hyun, Hakjun Choi, Min Joo Heo, Jung Yeon Seo, Yu Bin Nham, Eliel Yoon, Jin Gu Seong, Hye Noh, Ji Yun Cheong, Hee Jin Kim, Woo Joo Choi, Ju-Yeon Lee, Young Jae Lee, Hye Won Kim, Sung Soon Kim, Byoungguk Song, Joon Young J Korean Med Sci Original Article BACKGROUND: As the coronavirus disease 2019 (COVID-19) pandemic continues, there are concerns regarding waning immunity and the emergence of viral variants. The immunogenicity of Ad26.COV2.S against wild-type (WT) and variants of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) needs to be evaluated. METHOD: This prospective cohort study was conducted between June 2021 and January 2022 at two university hospitals in South Korea. Healthy adults who were scheduled to be vaccinated with Ad26.COV2.S were enrolled in this study. The main outcomes included anti-spike (S) IgG antibody and neutralizing antibody responses, S-specific T-cell responses (interferon-γ enzyme-linked immunospot assay), solicited adverse events (AEs), and serious AEs. RESULTS: Fifty participants aged ≥ 19 years were included in the study. Geometric mean titers (GMTs) of anti-S IgG were 0.4 U/mL at baseline, 5.2 ± 3.0 U/mL at 3–4 weeks, 55.7 ± 2.4 U/mL at 5–8 weeks, and 81.3 ± 2.5 U/mL at 10–12 weeks after vaccination. GMTs of 50% neutralizing dilution (ND50) against WT SARS-CoV-2 were 164.6 ± 4.6 at 3-4 weeks, 313.9 ± 3.6 at 5–8 weeks, and 124.4 ± 2.6 at 10–12 weeks after vaccination. As for the S-specific T-cell responses, the median number of spot-forming units/10(6) peripheral blood mononuclear cell was 25.0 (5.0–29.2) at baseline, 60.0 (23.3–178.3) at 5-8 weeks, and 35.0 (13.3–71.7) at 10–12 weeks after vaccination. Compared to WT SARS-CoV-2, ND50 against Delta and Omicron variants was attenuated by 3.6-fold and 8.2-fold, respectively. The most frequent AE was injection site pain (82%), followed by myalgia (80%), fatigue (70%), and fever (50%). Most AEs were grade 1–2, and resolved within two days. CONCLUSION: Single-dose Ad26.COV2.S was safe and immunogenic. NAb titer and S-specific T-cell immunity peak at 5–8 weeks and rather decrease at 10–12 weeks after vaccination. Cross-reactive neutralizing activity against the Omicron variant was negligible. The Korean Academy of Medical Sciences 2022-06-28 /pmc/articles/PMC9274104/ /pubmed/35818701 http://dx.doi.org/10.3346/jkms.2022.37.e210 Text en © 2022 The Korean Academy of Medical Sciences. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (https://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Original Article
Hyun, Hakjun
Choi, Min Joo
Heo, Jung Yeon
Seo, Yu Bin
Nham, Eliel
Yoon, Jin Gu
Seong, Hye
Noh, Ji Yun
Cheong, Hee Jin
Kim, Woo Joo
Choi, Ju-Yeon
Lee, Young Jae
Lee, Hye Won
Kim, Sung Soon
Kim, Byoungguk
Song, Joon Young
Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
title Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
title_full Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
title_fullStr Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
title_full_unstemmed Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
title_short Immunogenicity and Reactogenicity of Ad26.COV2.S in Korean Adults: A Prospective Cohort Study
title_sort immunogenicity and reactogenicity of ad26.cov2.s in korean adults: a prospective cohort study
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9274104/
https://www.ncbi.nlm.nih.gov/pubmed/35818701
http://dx.doi.org/10.3346/jkms.2022.37.e210
work_keys_str_mv AT hyunhakjun immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT choiminjoo immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT heojungyeon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT seoyubin immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT nhameliel immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT yoonjingu immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT seonghye immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT nohjiyun immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT cheongheejin immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT kimwoojoo immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT choijuyeon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT leeyoungjae immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT leehyewon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT kimsungsoon immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT kimbyoungguk immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy
AT songjoonyoung immunogenicityandreactogenicityofad26cov2sinkoreanadultsaprospectivecohortstudy